Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01454102
Title Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Bevacizumab

Ipilimumab

Cisplatin

Pemetrexed Disodium

Gemcitabine

Erlotinib

Carboplatin

Paclitaxel

Nivolumab

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.